Therefore, therapeutic approaches to inhibit and down-regulate AT1R-B2R aggregates aim not only to alleviate acute preeclampsia symptoms but also counteract and prevent long-term complications of preeclampsia, and other disorders associated with increased pathological AT1R-B2R aggregation. Here, BDKRB2 is linked to preeclampsia.